Kymriah (tisagenlecleucel/CTL019), for which Oxford BioMedica (OXB) provides the key lentiviral vector component, has been approved by the FDA for the treatment of patients up to 25 years of age with refractory/relapsed (second or later relapse) B-cell acute lymphoblastic leukaemia (ALL). Novartis has announced that the price for the one-off treatment will be $475k (c £370k), an increase over our previous assumption of £300k. We have updated our model to reflect the higher price,
01 Sep 2017
Kymriah approved - royalties to OXB assured
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Kymriah approved - royalties to OXB assured
- Published:
01 Sep 2017 -
Author:
Dr Daniel Wilkinson -
Pages:
3
Kymriah (tisagenlecleucel/CTL019), for which Oxford BioMedica (OXB) provides the key lentiviral vector component, has been approved by the FDA for the treatment of patients up to 25 years of age with refractory/relapsed (second or later relapse) B-cell acute lymphoblastic leukaemia (ALL). Novartis has announced that the price for the one-off treatment will be $475k (c £370k), an increase over our previous assumption of £300k. We have updated our model to reflect the higher price,